The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Lecanemab: Appropriate Use Recommendations
Open accessAbstract
Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid pathology. Appropriate Use Recommendations (AURs) are intended to help guide the introduction of new therapies into real-world clinical practice. Community dwelling patients with AD differ from those participating in clinical trials. Administration of lecanemab at clinical trial sites by individuals experienced with monoclonal antibody therapy also differs from the community clinic-based administration of lecanemab. These AURs use clinical trial data as well as research and care information regarding AD to help clinicians administer lecanemab with optimal safety and opportunity for effectiveness. Safety and efficacy of lecanemab are known only for patients like those participating in the phase 2 and phase 3 lecanemab trials, and these AURs adhere closely to the inclusion and exclusion criteria of the trials. Adverse events may occur with lecanemab including amyloid related imaging abnormalities (ARIA) and infusion reactions. Monitoring guidelines for these events are detailed in this AUR. Most ARIA with lecanemab is asymptomatic, but a few cases are serious or, very rarely, fatal. Microhemorrhages and rare macrohemorrhages may occur in patients receiving lecanemab. Anticoagulation increases the risk of hemorrhage, and the AUR recommends that patients requiring anticoagulants not receive lecanemab until more data regarding this interaction are available. Patients who are apolipoprotein E ε4 (APOE4) gene carriers, especially APOE4 homozygotes, are at higher risk for ARIA, and the AUR recommends APOE genotyping to better inform risk discussions with patients who are lecanemab candidates. Clinician and institutional preparedness are mandatory for use of lecanemab, and protocols for management of serious events should be developed and implemented. Communication between clinicians and therapy candidates or those on therapy is a key element of good clinical practice for the use of lecanemab. Patients and their care partners must understand the potential benefits, the potential harms, and the monitoring requirements for treatment with this agent. Culture-specific communication and building of trust between clinicians and patients are the foundation for successful use of lecanemab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lecanemab has a boxed warning for serious and symptomatic ARIA and requires testing for APOE ε4 prior to initiation as homozygosity increases risk.(510)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [510]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently, anti-amyloid monoclonal antibodies require the confirmation of amyloid-β pathology from PET or CSF before initiating therapy45,46.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, although patients with early-stage AD may be candidates for anti-amyloid therapies15–17, the coexistence of pathology from other etiologies, such as VD, can increase the risk of amyloid-related imaging abnormalities18.”
From AI-based differential diagnosis of dementia etiologies on multimodal data (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The risk of developing these potentially serious adverse effects is higher in APOEε4 carriers, particularly homozygotes, and current recommendations are that patients are genotyped for APOE before starting these therapies to offer a balanced benefit–risk discussion190.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [190]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Plasma biomarkers may therefore have an important role in reducing the patient burden associated with the initiation of anti-amyloid-β therapies for AD, which at present require biomarker confirmation with PET or CSF, as well as serial magnetic resonance imaging to monitor for adverse events45,46.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“Individuals with two copies of the APOE‐e4 gene are at increased risk of developing ARIA.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“Accordingly, ApoE genotyping is now increasingly considered an important component of the pre-treatment work-up for anti-amyloid therapies [5, 8, 11, 12].”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Self-citationLecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Self-citationMR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging
Fazekas, F., Chawluk, J. B., Alavi, A. A., Hurtig, H. I., & Zimmerman, R. A. (1987) · American Journal of Roentgenology · doi:10.2214/ajr.149.2.351 · Cited by 5,327
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Self-citation
Flagged first, then by citations
1 of the 62 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Irizarry M, van Dyck C, Sabbagh M, Bateman RJ, S. C, editors. Clarity AD: A phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer's disease. 15th Clinical Trials on Alzheimer's Disease Conference; 2022; San Francisco, CA USA.
Cited by
Sorted by citations
Items 101–200 of 961
Kelly, L., Brown, C., Michalik, D., Hawkes, C. A., Aldea, R., Agarwal, N., Salib, R. J., Alzetani, A., Ethell, D. W., Counts, S., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13512 · Cited by 31
The Sigma Receptors in Alzheimer’s Disease: New Potential Targets for Diagnosis and Therapy
Wang, T., & Jia, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512025 · Cited by 30
Symptom‐based staging for logopenic variant primary progressive aphasia
Hardy, C. J. D., Taylor‐Rubin, C., Taylor, B., Harding, E., Gonzalez, A. S., Jiang, J., Thompson, L., Kingma, R. M., Chokesuwattanaskul, A., Walker, F., et al. (2024) · European Journal of Neurology · doi:10.1111/ene.16304 · Cited by 26
Farrar, G., Weber, C. J., & Rabinovici, G. D. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100008 · Cited by 27
Self-citationTonegawa‐Kuji, R., Hou, Y., Hu, B., Lorincz‐Comi, N. J., Pieper, A. A., Tousi, B., Leverenz, J. B., & Cheng, F. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004568 · Cited by 30
Salemme, S., Ancidoni, A., Locuratolo, N., Piscopo, P., Lacorte, E., Canevelli, M., & Vanacore, N. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2284305 · Cited by 28
Rentz, D. M., Aisen, P. S. S., Atri, A., Hitchcock, J. M., Irizarry, M. C., Landen, J. W., Matthews, B. R., Miller, D. S., Mahinrad, S., Napoli, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14199 · Cited by 28
Self-citationDeterminants of dementia diagnosis in U.S. primary care in the past decade: A scoping review
Cox, C. G., Brush, B. L., Kobayashi, L. C., & Roberts, J. S. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100035 · Cited by 34
Panza, F., Dibello, V., Sardone, R., Zupo, R., Castellana, F., Leccisotti, I., Moretti, M. C., Altamura, M., Bellomo, A., Daniele, A., et al. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2463963 · Cited by 28
Amyloid-β aggregates activate peripheral monocytes in mild cognitive impairment
Juul‐Madsen, K., Parbo, P., Ismail, R., Ovesen, P. L., Schmidt, V., Madsen, L. S., Thyrsted, J., Gierl, S., Breum, M., Larsen, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45627-y · Cited by 31
Jeong, S. Y., Suh, C. H., Kim, S. J., Lemere, C. A., Lim, J.-S., & Lee, J.-H. (2024) · Korean Journal of Radiology · doi:10.3348/kjr.2024.0105 · Cited by 26
“The FDA guidelines for the clinical use of lecanemab also suggest the same exclusion criteria for hemorrhage [11].”
BackgroundMethodInfluentialAmyloid-lowering monoclonal antibodies for the treatment of early Alzheimer’s disease
Leisher, S., Bohorquez, A., Gay, M., Garcia, V., Jones, R., Baldaranov, D., & Rafii, M. S. (2023) · CNS Drugs · doi:10.1007/s40263-023-01021-8 · Cited by 26
Jy, L., Wong, C.-Y., Koh, R. Y., Lim, C. L., Kok, Y.-Y., & Chye, S. M. (2024) · The Yale Journal of Biology and Medicine · doi:10.59249/jnkb9714 · Cited by 26
Howe, M. D., Britton, K. J., Joyce, H. E., Menard, W. E., Emrani, S., Kunicki, Z. J., Faust, M. A., Dawson, B. C., Riddle, M. C., Huey, E. D., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01521-9 · Cited by 30
Self-citationHackett, K., Xu, S., McKniff, M., Paglia, L., Barnett, I., & Giovannetti, T. (2024) · JMIR Human Factors · doi:10.2196/59974 · Cited by 27
A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies
Hering, H., Bussière, T., Liu, C., Glajch, K. E., Weihofen, A., Grogan, J. L., & Walsh, D. M. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00872-7 · Cited by 28
Donanemab for Alzheimer’s disease: from preclinical research to the clinical application
Dodel, R. C., & Froelich, L. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2546868 · Cited by 27
Sonwani, A., Pathak, A., & Jain, K. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105855 · Cited by 25
Jessen, F., Kramberger, M. G., Angioni, D., Aarsland, D., Balasa, M., Bennys, K., Boada, M., Boban, M., Chincarini, A., Exalto, L. G., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.153 · Cited by 23
Vukmir, R. B. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52042 · Cited by 24
Gibson, A. W., Elser, H. C., Rosso, M., Cornblath, E. J., Fonkeu, Y., Prasad, S., Rothstein, A., Nasrallah, I. M., Wolk, D. A., & Guo, M. H. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14223 · Cited by 23
Bobbins, A., Davies, M., Lynn, E., Roy, D., Yeomans, A., & Shakir, S. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70021 · Cited by 24
Cordonnier, C., Klijn, C. J. M., Smith, E. E., Salman, R. A., Chwalisz, B. K., van Etten, E. S., Muir, R. T., Piazza, F., Schreiber, S., Schreuder, F. H. B. M., et al. (2025) · International Journal of Stroke · doi:10.1177/17474930251365861 · Cited by 23
Self-citationCurrent status of amyloid-targeting immunotherapies for Alzheimer’s disease
Tabor, G. T., & Holtzman, D. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adk9993 · Cited by 23
Omaveloxolone ameliorates cognitive dysfunction in APP/PS1 mice by stabilizing the STAT3 pathway
Cui, X., Zong, S., Song, W., Wang, C., Liu, Y., Zhang, L., Xia, P., Wang, X., Zhao, H., Wang, L., et al. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122261 · Cited by 23
Galvin, J. E., Cummings, J. L., Benea, M. L., de Moor, C., Allegri, R., Atri, A., Chertkow, H. M., Paquet, C., Porter, V. R., Ritchie, C. W., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13785 · Cited by 22
Self-citationAdvancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review
Beshir, S. A., Hussain, N., Menon, V. B., Haddad, A. H. I. A., Zeer, R. A. K. A., & Elnour, A. A. (2024) · International Journal of Alzheimer s Disease · doi:10.1155/2024/2052142 · Cited by 32
Aljuhani, M., Ashraf, A., & Edison, P. (2024) · Brain Communications · doi:10.1093/braincomms/fcae435 · Cited by 25
Pérez, S. S., Bringas, G., Amable, N. U., Peñalver, A. I., López, D., Dalmau, E. G., Fernández, A., Hernández-Díaz, Z. M., Vina-Rodrı́guez, A., Peña, Y., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01356-w · Cited by 22
Brain perfusion SPECT in dementia: what radiologists should know
Imokawa, T., Yokoyama, K., Takahashi, K., Oyama, J., Tsuchiya, J., Sanjo, N., & Tateishi, U. (2024) · Japanese Journal of Radiology · doi:10.1007/s11604-024-01612-5 · Cited by 21
Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease
Rosen, J., & Jessen, F. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100102 · Cited by 21
Claus, J. J., Hofe, I. V., Veenstra, A. V. I., Licher, S., Seelaar, H., de Jong, F. J., Neitzel, J., Vernooij, M. W., Ikram, M. A., & Wolters, F. J. (2025) · European Journal of Epidemiology · doi:10.1007/s10654-025-01220-1 · Cited by 24
Wang, H., Pan, J., Zhang, M., & Tan, Z. F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1599048 · Cited by 28
Tideman, P., Karlsson, L., Strandberg, O. T., Calling, S., Smith, R. A., Midlöv, P., Verghese, P. B., Braunstein, J. B., Mattsson, N., Stomrud, E., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03965-4 · Cited by 36
Anti-Amyloid Therapies for Alzheimer’s Disease: Progress, Pitfalls, and the Path Ahead
Papaliagkas, V. T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199529 · Cited by 21
Gut instincts: Unveiling the connection between gut microbiota and Alzheimer's disease
Peddinti, V., Avaghade, M. M., Suthar, S. U., Rout, B., Gomte, S. S., Agnihotri, T. G., & Jain, A. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.02.019 · Cited by 24
Research Progress on the Pathogenesis, Diagnosis, and Drug Therapy of Alzheimer’s Disease
Yang, Y., & Qiu, L. (2024) · Brain Sciences · doi:10.3390/brainsci14060590 · Cited by 22
Accelerating Parkinson’s Disease drug development with federated learning approaches
Khanna, A., Adams, J., Antoniades, C., Bloem, B. R., Carroll, C., Cedarbaum, J., Cosman, J., Dexter, D. T., Dockendorf, M. F., Edgerton, J., et al. (2024) · npj Parkinson's Disease · doi:10.1038/s41531-024-00837-5 · Cited by 21
Use of Artificial Intelligence in Imaging Dementia
Aljuhani, M., Ashraf, A., & Edison, P. (2024) · Cells · doi:10.3390/cells13231965 · Cited by 21
ACR Appropriateness Criteria® Dementia: 2024 Update
Soderlund, K. A., Austin, M. J., Ben‐Haim, S., Chu, S., Ivanidze, J., Joshi, P., Kalnins, A., Kennedy, M., Kulshreshtha, A., Kuo, P. H., et al. (2025) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2025.02.031 · Cited by 22
Elbatrawy, A. A., Ademoye, T. A., Alnakhala, H., Tripathi, A., Zami, A., Ostafe, R., Dettmer, U., & Fortin, J. S. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117613 · Cited by 20
Oh, E. S. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-02207 · Cited by 28
Chen, S., Ou, R., Wei, Q., Li, C., Wei, S., Zhao, B., Yang, H. J., Fu, J., Ma, Y., Liu, J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70750 · Cited by 19
Clinical characteristics of pathological confirmed prodromal dementia with Lewy bodies
Ting, S. K. S., Saffari, S. E., Hameed, S., Chiew, H. J., Ng, K. P., & Ng, A. S. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.120815 · Cited by 19
Aye, S., Handels, R. L. H., Winblad, B. G., & Jönsson, L. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.67 · Cited by 19
Rosenbloom, M. H., O’Donohue, T., Zhou-Clark, D., Mala, D., Frazier, A., Tarrant, M., Modrijan, M., Riveira, M. C., Chapman, D., Griffin, Y., et al. (2024) · CNS Drugs · doi:10.1007/s40263-024-01097-w · Cited by 20
Kumar, S., Earnest, T., Yang, B., Kothapalli, D., Aschenbrenner, A. J., Hassenstab, J. J., Xiong, C., Ances, B. M., Morris, J. C., Benzinger, T. L. S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70143 · Cited by 20
Wu, Y., Yang, L., Jiang, W., Zhang, X., & Yao, Z. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00190 · Cited by 19
Defrancesco, M., Gizewski, E. R., Mangesius, S., Galijašević, M., Virgolini, I. J., Kroiss, A. S., Marksteiner, J., Jehle, J., Doganyigit, B., & Hofer, A. (2024) · BJPsych Open · doi:10.1192/bjo.2024.747 · Cited by 18
Logroscino, G., Urso, D., Gnoni, V., Giugno, A., Vilella, D., Castri, A. D., Barone, R. M. E., Nigro, S. L., Zecca, C., Blasi, R. D., et al. (2024) · European Journal of Neurology · doi:10.1111/ene.16534 · Cited by 18
Blood-Based Biomarkers and Risk of Onset of Mild Cognitive Impairment Over the Short and Long Term
Soldan, A., Pettigrew, C. A., Wang, J., Albert, M., Blennow, K., Bittner, T., & Moghekar, A. (2024) · Neurology · doi:10.1212/wnl.0000000000210225 · Cited by 22
Imaging and Fluid Biomarkers of Alzheimer Disease: Complementation Rather Than Competition
Drzezga, A. E., & Barthel, H. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270152 · Cited by 18
The Healthy Brain Initiative (HBI): A prospective cohort study protocol
Besser, L. M., Chrisphonte, S., Kleiman, M. J., O’Shea, D. M., Rosenfeld, A., Tolea, M. I., & Galvin, J. E. (2023) · PLoS ONE · doi:10.1371/journal.pone.0293634 · Cited by 20
Use of Lecanemab for Patients With Cardiovascular Disease
Ko, D., Pascual‐Leone, Á., & Shah, S. J. (2024) · JAMA · doi:10.1001/jama.2024.2991 · Cited by 18
Abdelazim, K., Allam, A. A., Afifi, B., Abdulazeem, H. M., & Elbehiry, A. I. (2024) · Neurological Sciences · doi:10.1007/s10072-024-07477-w · Cited by 18
Implications of Emerging Uses of Genetic Testing for Alzheimer's Disease
Blasco, D., & Roberts, J. S. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.46 · Cited by 18
Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease
Aye, S., Johansson, G., Höck, C., Lannfelt, L., Sims, J. R., Blennow, K., Frederiksen, K. S., Graff, C., Molinuevo, J. L., Scheltens, P., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100022 · Cited by 17
Gillman, A., Bourgeat, P., Cox, T. O., Villemagne, V. L., Fripp, J., Huang, K., Williams, R. C., Shishegar, R., O'Keefe, G. J., Li, S., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241313063 · Cited by 17
CRISPR in Neurodegenerative Diseases Treatment: An Alternative Approach to Current Therapies
Akbar, A., Haider, R., Agnello, L., Noor, B., Maqsood, N., Atif, F., Ali, W., Ciaccio, M., & Tariq, H. (2025) · Genes · doi:10.3390/genes16080850 · Cited by 21
Bumber, J. R., Rački, V., Mežnarić, S., Pelčić, G., & Mršić‐Pelčić, J. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176047 · Cited by 19
Sato, K., Niimi, Y., Ihara, R., Iwata, A., Nemoto, K., Arai, T., Higashi, S., Igarashi, A., Kasuga, K., Akiyama, H., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70652 · Cited by 17
The Role of Amyloid- and Tau PET in the New Era of Alzheimer Disease Therapies
Chiotis, K., Wang, Y., Joie, R. L., & Rabinovici, G. D. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268339 · Cited by 18
Self-citationWang, S., Kang, D. W., Um, Y. H., Kim, S., Lee, C. U., & Lim, H. K. (2023) · Biomolecules · doi:10.3390/biom13091336 · Cited by 17
Blood‐based biomarkers in Alzheimer's disease: Future directions for implementation
Suridjan, I., van der Flier, W. M., Monsch, A. U., Burnie, N., Baldor, R. A., Sabbagh, M. N., Vilaseca, J., Cai, D., Carboni, M., & Lah, J. J. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12508 · Cited by 15
Adapting prescribing criteria for amyloid‐targeted antibodies for adults with Down syndrome
Hillerstrom, H., Fisher, R. A., Janicki, M. P., Chicoine, B. A., Christian, B. T., Esbensen, A. J., Esralew, L., Fortea, J., Hartley, S. L., Hassenstab, J. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13778 · Cited by 17
Azargoonjahromi, A. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgae066 · Cited by 17
Quispialaya, K. M., Therriault, J., Aliaga, A., Benedet, A. L., Ashton, N. J., Karikari, T. K., Macedo, A. C., Rahmouni, N., Tissot, C., Arias, J. F., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000210211 · Cited by 17
Tsuchida, A., Goubet, M., Boutinaud, P., Astafeva, I., Nozais, V., Hervé, P., Tourdias, T., Debette, S., & Joliot, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-81870-5 · Cited by 19
Advancements in the treatment of Alzheimer's disease: a comprehensive review
Rajanna, S., Gundale, P. P., & Mahadevaiah, A. D. (2025) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-0204 · Cited by 20
“Real‐world” eligibility for anti‐amyloid treatment in a tertiary memory clinic setting
Vigneswaran, S., Vijverberg, E. G. B., Barkhof, F., van de Giessen, E., Lemstra, A. W., Pijnenburg, Y. A. L., Teunissen, C. E., van der Flier, W. M., & van Harten, A. C. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70375 · Cited by 18
Barroeta, I., Videla, L., Carmona‐Iragui, M., Fortea, J., & Rafii, M. S. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70258 · Cited by 18
Kapasi, A., James, B. D., Yu, L., Sood, A., Arvanitakis, Z., Bennett, D. A., Boyle, P. A., & Schneider, J. A. (2025) · Neurology · doi:10.1212/wnl.0000000000214004 · Cited by 20
Bhujbal, S. P., & Hah, J. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01566-w · Cited by 17
Howe, M. D., Britton, K. J., Joyce, H. E., Pappas, G. J., Faust, M. A., Dawson, B. C., Riddle, M. C., & Salloway, S. P. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.96 · Cited by 15
Self-citationAckley, S. F., Wang, J., Chen, R., Power, M. C., Allen, I. E., & Glymour, M. M. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13470 · Cited by 14
Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms
Vuić, B., Milos, T., Tudor, L., Perković, M. N., Konjevod, M., Erjavec, G. N., Farkaš, V., Uzun, S., Mimica, N., & Štrac, D. Š. (2023) · Genes · doi:10.3390/genes14112048 · Cited by 17
Now and future: Strategies for diagnosis, prevention and therapies for Alzheimer’s disease
Shi, J., Touchon, J., Middleton, L. T., Boada, M., Vassar, R. J., Vellas, B. J., & Shen, Y. (2024) · 中国科学通报：英文版 · doi:10.1016/j.scib.2024.09.042 · Cited by 16
Sato, K., Niimi, Y., Ihara, R., Iwata, A., Suzuki, K., Nemoto, K., Arai, T., Higashi, S., Igarashi, A., Kasuga, K., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01568-8 · Cited by 16
Gulline, H., Carmody, S., Yates, M. W., Bevins, A., Brodtmann, A. G., Loi, S. M., Lim, Y. Y., Macklin, H., Glennen, K., Woodward, M., et al. (2025) · International Journal for Equity in Health · doi:10.1186/s12939-025-02434-1 · Cited by 17
Donanemab eligibility in early Alzheimer's disease: A real-world study
Urso, D., Introna, A., Gnoni, V., Giugno, A., Vilella, D., Zecca, C., Blasi, R. D., Giannoni‐Luza, S., & Logroscino, G. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251331243 · Cited by 16
Immunotherapeutic approaches for Alzheimer’s disease: Exploring active and passive vaccine progress
Bhadane, P., Roul, K., Belemkar, S., & Kumar, D. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149018 · Cited by 15
Chan, V. T. T., Ran, A. R., Wagner, S. K., Hui, H. Y. H., Hu, X., Ko, H., Fekrat, S., Wang, Y. X., Lee, C. S., Young, A. L., et al. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101290 · Cited by 15
Proposed Mechanisms of Cell Therapy for Alzheimer’s Disease
Belousova, E., Salikhova, D. I., Maksimov, Y., Nebogatikov, V. O., Sudina, A. K., Goldshtein, D. V., & Ustyugov, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212378 · Cited by 17
Videla, L., Benejam, B., Barroeta, I., Fernández, S., Altuna, M., Arranz, J., Rodríguez‐Baz, Í., Arriola‐Infante, J. E., Maure‐Blesa, L., Soriano, L. D. H., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70259 · Cited by 17
Benussi, A., Agosta, F., Alfano, A. R., Antico, A., Bellelli, G., Bonanni, L., Bottini, G., Bozzali, M., Brignoli, O., Bruno, G., et al. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08576-y · Cited by 17
Towards pharmacological prevention of Alzheimer disease
Llibre‐Guerra, J. J., McDade, E., Schindler, S. E., Clifford, D. B., Supnet, C. B., Atri, A., & Bateman, R. J. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01154-y · Cited by 18
Self-citationBabulal, G. M., Chen, L., Murphy, S. A., Doherty, J. M., Johnson, A. M., & Morris, J. C. (2023) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.07.012 · Cited by 15
Patterns of use of symptomatic treatments for Alzheimer's disease dementia (AD)
DiBello, J. R., Lü, Y., Swartz, J., Bortnichak, E. A., Liaw, K., Zhong, W., & Liu, X. (2023) · BMC Neurology · doi:10.1186/s12883-023-03447-5 · Cited by 15
Addressing challenges in health care and research for people with Down syndrome
Fortea, J., McGlinchey, E., Espinosa, J. M., & Rafii, M. S. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00478-1 · Cited by 15
Alzheimer's disease biomarkers and the tyranny of treatment
Karlawish, J. H., & Grill, J. D. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105291 · Cited by 15
Rosenbloom, M. H., Schnee, A., Nimma, S., Lutz, H., Gzesh, D. J., & Weisman, D. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13142-9 · Cited by 14
Bereczki, E., Mangialasche, F., Barbera, M., Padilla, P. M., Hara, Y., Fillit, H. M., Solomon, A., & Kivipelto, M. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100367 · Cited by 17
Liao, W., Yu, Q., Chen, B., Chen, H., Zou, L., Xie, H., Chen, H., Wang, C., Li, Y., Gao, X., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71231 · Cited by 14
Updates on pharmacological treatment for Alzheimer’s disease
Tipton, P. W. (2023) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.96286 · Cited by 16
Lu, O., Kouser, T., & Skylar‐Scott, I. A. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1241339 · Cited by 14
Focusing on earlier diagnosis of Alzheimer's disease
Frederiksen, K. S., Morató, X., Zetterberg, H., Gauthier, S. G., Boada, M., Pytel, V., Hahn-Pedersen, J. H., Tarazona, L. R. S., & Mattke, S. (2024) · Future Neurology · doi:10.2217/fnl-2023-0024 · Cited by 14
Chen, X., Becker, A., Albay, R., Nguyen, P. D., Karachentsev, D., Roberts, A. J., Rynearson, K. D., Tanzi, R. E., & Mobley, W. C. (2024) · Annals of Neurology · doi:10.1002/ana.26958 · Cited by 14
Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
Wicker, A., Shriram, J., Decourt, B., & Sabbagh, M. N. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00664-z · Cited by 15
Wang, H., Chao, L., Shen, S., You, P., Li, L., Chen, X., Hong, Z., & Chai, Y. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119994 · Cited by 13
ApoE-calypse tau: ApoE–tau synergy in Alzheimer’s disease
Lennol, M. P., Bordier, C., Kamelher, L., Ulrich, J. D., Holtzman, D. M., & Gratuze, M. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20250965 · Cited by 14
Metadata
- Authors
- Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., & Salloway, S.
- Affiliations
- Indiana University Indianapolis (US)
- University of California, San Francisco (US)
- Banner Health (US)
- University of Southern California (US)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Brown University (US)
- Venue
- The Journal of Prevention of Alzheimer's Disease
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 10
- Issue
- 3
- Pages
- 362-377
- ISSN
- 2274-5807 (ISSN-L)
- PMC
- PMC10313141
- OpenAlex
- W4360591479
- Cited by
- 961
- References
- 62
- Citations by year
- 2026: 335 · 2025: 305 · 2024: 249 · 2023: 71
- FWCI
- 170.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Journal of Prevention of Alzheimer s Disease (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- Foundation for the National Institutes of Health (R35AG71476, U01NS093334, P20GM109025, P30AG072959, P30 AG010133, R01AG053798, R01 AG057739)
- Alzheimer's Association (P30 AG010133)
- Alzheimer's Drug Discovery Foundation (P20GM109025)
- Eli Lilly and Company (P20GM109025)
- Biogen (P20GM109025)
- University of Southern California (P20GM109025)
- Patient-Centered Outcomes Research Institute
- Alnylam Pharmaceuticals
- BioClinica (P20GM109025)
- Sunovion
- Buck Institute for Research on Aging
- Prothena
- University of Oxford
- Eisai (P20GM109025)
- Novo Nordisk
- Shionogi
- H. Lundbeck A/S (P20GM109025)
- Grifols
- Nestec
- National Institutes of Health (RD005665)
- Genentech (P20GM109025)
- Allergan
- Avid Radiopharmaceuticals
- National Institute on Aging (AG010133, P30AG010133, U01AG057195, NIA U01 AG057195, R01AG053798, P20AG068053, NIA P30 AG010133, R01AG057739, R35AG71476, P30AG072959, P30AG072980, R35AG071476)
- National Institute of General Medical Sciences (P20GM109025)
- National Institute of Neurological Disorders and Stroke (U01NS093334)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- lecanemab, Alzheimer's disease, amyloid-related imaging abnormalities, amyloid plaques, mild cognitive impairment, early Alzheimer's disease, bleeding risk, anticoagulation, infusion reactions, monoclonal antibody therapy, caregiver-patient communication, clinical preparedness
- MeSH terms
- Alzheimer Disease, Amyloid, Antibodies, Monoclonal, Humans, Apolipoprotein E4, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
